Corvus Pharmaceuticals, Inc.
CRVSHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation. Valued at $1.25B, CRVS is a small-cap name in its sector. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Market Cap
$1.25B
Beta
0.82
P/E (TTM)
—
P/E (Fwd)
-15.74
EPS (TTM)
$-0.57
EPS (Fwd)
$-0.95
ROE
-30.5%
ROA
-19.2%
Cash
$236.7M
Total Debt
$834,000
Free CF
-$22.6M
52W Change
249.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $236.7M in cash comfortably exceeding the $834K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$22.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -30.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CRVS.